Patents Examined by Philip W. Carter
  • Patent number: 5240840
    Abstract: Superfragments of chromosomal DNA having 1 million to 100 million base pairs may be formed by irradiating microcells containing a chromosome with a high dose of .gamma.-irradiation. Such superfragments are useful for the rapid cloning of genes.
    Type: Grant
    Filed: April 5, 1991
    Date of Patent: August 31, 1993
    Assignee: Regents of the University of Michigan
    Inventors: Andrew P. Feinberg, Minoru Koi
  • Patent number: 5238834
    Abstract: The present invention is directed to recombinant DNA vector molecules and uses therefor. More particularly, the present invention relates to the construction of recombinant vectors useful in the high frequency cloning of cDNA. The present invention also relates to vectors capable of directing the synthesis of single stranded cDNA and thereby permitting enrichment of specific sequences by hybridization/selection.
    Type: Grant
    Filed: May 22, 1992
    Date of Patent: August 24, 1993
    Assignee: Health Research, Inc.
    Inventor: Steven C. Pruitt
  • Patent number: 5229283
    Abstract: The present invention provides improved methods for manipulating recombinant DNA in gene cloning and expression. More specifically, the invention provides methods capable of altering a nucleic acid sequence present at the termini of a target sequence.
    Type: Grant
    Filed: May 8, 1992
    Date of Patent: July 20, 1993
    Assignee: Life Technologies, Inc.
    Inventor: Mark S. Berninger
  • Patent number: 5223408
    Abstract: A screening method for the selection of mutagenized proteins that are normally secreted by cells is described. The method includes the development of a cloning vector for the expression of secretory proteins as fusion proteins on the cell surface of transfected mammalian cells. The secreted protein is displayed on the cell surface by fusion with the glycophospholipid membrane anchor of decay accelerating factor (DAF). Tissue-type plasminogen activator (t-PA), which is normally secreted, is used as a model protein. PCR mutagenesis is used to generate random mutations within the Kringle 1 (K1) domain of t-PA. Fluorescence activated cell sorting (FACS) is employed to screen for t-PA mutants possessing a loss of an epitope to a specific Mab, whose nonlinear binding domains overlap with the t-PA clearance receptor contact regions novel t-PA mutants designated N115S, N1425S, and K159R were discovered by this method.
    Type: Grant
    Filed: July 11, 1991
    Date of Patent: June 29, 1993
    Assignee: Genentech, Inc.
    Inventors: David V. Goeddel, Glenn C. Rice, David W. H. Leung
  • Patent number: 5223424
    Abstract: The present invention provides a recombinant fusion protein comprising an antigenic amino acid sequence fused to at least a portion of the gpX glycoprotein from pseudorabies virus. Such a protein may be formulated into a vaccine and delivered to an animal using a live herpesvirus vector adapted to express the fusion protein.
    Type: Grant
    Filed: July 27, 1988
    Date of Patent: June 29, 1993
    Assignee: Prutech Research And Development
    Inventors: Mark D. Cochran, Christina H. Chiang, Richard D. MacDonald
  • Patent number: 5223610
    Abstract: The present invention contemplates a method of physiologic engineering by genetically altering second messenger levels in cells. This method allows the hyperactivation or inhibition of cell function within cells, tissues and animals by introducing a foreign gene that alters a second messenger system. The use of physiologically engineered animals as systems for determining the effectiveness of therapeutic compositions is also contemplated.
    Type: Grant
    Filed: May 18, 1990
    Date of Patent: June 29, 1993
    Assignee: The Scripps Research Institute
    Inventors: Frank H. Burton, J. Gregor Sutcliffe
  • Patent number: 5217884
    Abstract: A process using microorganisms which contain genes, which form an active xylene monooxygenase, which form no effective, chromosomally or plasmid-coded alcohol hydrogenase, and which are, thus, capable of hydroxylating methyl groups on aromatic 5- or 6-atom heterocycles to the corresponding hydroxymethyl derivatives, for the production of hydroxymethylated 5- or 6-atom heterocycles.
    Type: Grant
    Filed: September 23, 1991
    Date of Patent: June 8, 1993
    Assignee: Lonza Ltd.
    Inventors: Thomas Zimmermann, Andreas Kiener, Shigeaki Harayama
  • Patent number: 5206163
    Abstract: The nucleotide sequence of the genome for bovine diarrhea virus (BDV) is disclosed. The sequence permits design and construction of vaccines effective against BDV.
    Type: Grant
    Filed: July 6, 1990
    Date of Patent: April 27, 1993
    Assignee: Chiron Corporation
    Inventors: Andre Renard, Dino Dina, Joseph Martial
  • Patent number: 5200341
    Abstract: An rpoH gene that encodes a .sigma..sup.32 protein in which cysteine instead of arginine is at amino acid residue 268 was isolated from a mutant of Escherichia coli strain W3110. The rpoH gene has thymine instead of cytosine at the nucleotide position corresponding to 802 in the wild-type rpoH gene. Purified strains of E. coli W3110 and JM101 having a mutant rpoH gene in which thymine instead of cytosine is at the nucleotide position corresponding to 802 in a wild-type rpoH gene and a method for synthesis of proteins at enhanced levels are also disclosed. The method comprises introducing an expression vehicle into an E. coli strain containing the mutant rpoH gene of this invention.
    Type: Grant
    Filed: October 7, 1991
    Date of Patent: April 6, 1993
    Assignee: Monsanto Company
    Inventor: Mark G. Obukowicz
  • Patent number: 5196318
    Abstract: The invention relates to an expression vector system based on the regulation of bacterial luminescence (the lux gene system). The invention further relates to the construction of a precisely regulatable expression vector system which comprises a complete luxR gene in combination with an inactivated luxI gene. If the system is turned off, no significant transcription occurs of any cloned gene product when used in combination with the regulatory scheme of the invention as is demonstrated by using the bacteriophage .lambda. lysis genes. The induction of transcription relies on the addition of exogenous autoinducer which is both inexpensive and easy-to-use and which is required in only minute amounts.
    Type: Grant
    Filed: June 26, 1990
    Date of Patent: March 23, 1993
    Assignee: The Texas A&M University System
    Inventors: Thomas O. Baldwin, Jerry H. Devine, Gerald S. Shadel
  • Patent number: 5196321
    Abstract: Methods of designing or modifying protein structure at the protein or genetic level to produce specified amino-termini in vivo or in vitro are described. The methods can be used to alter the metabolic stability and other properties of the protein or, alternatively, to artificially generate authentic amino-termini in proteins produced through artificial means. The methods are based upon the introduction of the use of artificial ubiquitin-protein fusions, and the discovery that the in vivo half-life of a protein is a function of the amino-terminal amino acid of the protein.
    Type: Grant
    Filed: January 15, 1992
    Date of Patent: March 23, 1993
    Assignee: Massachusetts Institute of Technology
    Inventors: Andreas Bachmair, Daniel Finley, Alexander Varshavsky
  • Patent number: 5187061
    Abstract: Viable bacteria may be detected in biological samples by exposing bacterial cultures obtained from the samples to transducing particles having a known host range. Such transducing particles carry a heterologous gene capable of altering the phenotype of the bacteria in a readily detectable manner. For example, the transducing particles may carry an ice nucleation gene and the alteration of phenotype may be detected using an ice nucleation assay. By employing a panel of phage, unknown bacteria nmay be typed based on the pattern of reactivity observed. The transducing particles may be prepared by introducing a synthetic transposable element carrying the heterologous gene to a host carrying a prophage having the desired host range. After transposition, the host may be induced to a lytic cycle to release the transducing particles carrying the heterologous gene.
    Type: Grant
    Filed: November 5, 1990
    Date of Patent: February 16, 1993
    Assignee: DNA Plant Technology Corporation
    Inventors: Neal I. Gutterson, William T. Tucker, Paul K. Wolber
  • Patent number: 5168056
    Abstract: A genetic element comprising an expression vector and a gene coding for transketolase is utilized to enhance diversion of carbon resources into the common aromatic pathway.
    Type: Grant
    Filed: February 8, 1991
    Date of Patent: December 1, 1992
    Assignee: Purdue Research Foundation
    Inventor: John W. Frost
  • Patent number: 5137814
    Abstract: The present invention provides improved methods for manipulating recombinant DNA in gene cloning and expression. More specifically, the invention provides methods capable of altering a nucleic acid sequence present at the termini of a target sequence.
    Type: Grant
    Filed: June 14, 1991
    Date of Patent: August 11, 1992
    Assignee: Life Technologies, Inc.
    Inventors: Ayoub Rashtchian, Mark S. Berninger